Investigators examined a link between major cardiovascular risk factors, such as older age and smoking, and venous thromboembolism, consisting of deep vein thrombosis or pulmonary embolism.
Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.
The American Society of Hematology has developed new guidelines for the treatment of venous thromboembolism.
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo.
The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.
A patient-centered education bundle intervention can reduce nonadministration of venous thromboembolism prophylaxis.
Patients with splanchnic vein thrombosis may be at an increased risk for bleeding and arterial cardiovascular events for years after diagnosis.
Rivaroxaban was associated with lower clinical event costs but higher total healthcare costs compared with aspirin in patients with venous thromboembolism.
Among patients undergoing total knee arthroplasty, aspirin alone may provide protection against postoperative VTE that is similar to that of other anticoagulants.
The likelihood of residual vein obstruction is reduced with immediate compression after diagnosis of deep vein thrombosis.